VWC2L
von Willebrand factor C domain-containing protein 2-like
Also known as: VWC2L_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- B2RUY7
- Gene
- VWC2L
- Ensembl
- ENSG00000174453
- Chromosome
- 2
- Canonical length
- 222 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted - unknown location
OverviewNCBI Gene
Predicted to be involved in negative regulation of BMP signaling pathway. Predicted to act upstream of or within positive regulation of neuron differentiation. Predicted to be located in extracellular region and synapse. Predicted to be part of AMPA glutamate receptor complex. Predicted to be active in extracellular space. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
222 residues, UniProt reviewed canonical sequence.
>B2RUY7|VWC2L
1 MALHIHEACI LLLVIPGLVT SAAISHEDYP ADEGDQISSN DNLIFDDYRG KGCVDDSGFV
61 YKLGERFFPG HSNCPCVCAL DGPVCDQPEC PKIHPKCTKV EHNGCCPECK EVKNFCEYHG
121 KNYKILEEFK PSPCEWCRCE PSNEVHCVVA DCAVPECVNP VYEPEQCCPV CKNGPNCFAG
181 TTIIPAGIEV KVDECNICHC HNGDWWKPAQ CSKRECQGKQ TVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against VWC2L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 2.4 nTPM
Expression across tissuesHPA
Tissue
- hypothalamus: 2.4 nTPM
- cerebral cortex: 1.9 nTPM
- midbrain: 1.3 nTPM
- retina: 1.3 nTPM
- amygdala: 0.6 nTPM
- hippocampal formation: 0.6 nTPM
Single-cell type
- epicardial cells: 150 nCPM
- thyrotrophs: 123 nCPM
- lactotrophs: 91 nCPM
- brain inhibitory neurons: 69 nCPM
- somatotrophs: 69 nCPM
- other brain neurons: 68 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 7.6 nTPM
- thalamus: 6.7 nTPM
- hypothalamus: 6.6 nTPM
- basal ganglia: 6.3 nTPM
- white matter: 5.9 nTPM
- midbrain: 5.6 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.8
- gnomAD pLI
- 0.13
- gnomAD missense Z
- 1.55
- DepMap mean gene effect
- 0.06
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads VWC2L as an antibody target. Whether an autoantibody or antibody against VWC2L could matter depends on whether native VWC2L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
VWC2L is annotated as secreted, so native VWC2L circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label VWC2L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...